Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 7/20 | 0.41 |
| ▸ | CLPP | Q16740 | 1/20 | 0.39 |
| ▸ | GRK2 | P25098 | 1/20 | 0.39 |
| ▸ | PARN | O95453 | 1/20 | 0.38 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702609 | 0.93 | MMP13 (0.46) | MMP13PDPK1 | |
| SCHEMBL6704150 | 0.77 | MDM4 (0.42) | PDPK1PARNCNOT7 | |
| SCHEMBL6701275 | 0.77 | IDO1 (0.48) | MMP13PDPK1CLPP | |
| SCHEMBL6701186 | 0.76 | MMP13 (0.41) | MMP13 | |
| SCHEMBL6298027 | 0.75 | MMP13 (0.81) | MMP13PDPK1 | |
| SCHEMBL6703285 | 0.74 | MMP13 (0.60) | MMP13 | |
| SCHEMBL6703449 | 0.74 | MMP13 (0.52) | MMP13 | |
| SCHEMBL6219427 | 0.73 | MMP13 (0.42) | MMP13PDPK1 | |
| SCHEMBL6814878 | 0.71 | ALDH1A1 (0.41) | MMP13 | |
| SCHEMBL6288786 | 0.70 | PLA2G7 (0.35) | MMP13CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 13/4885PDPK1 2688/4885CLPP 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.